» Articles » PMID: 38193894

BRAIDing Receptors for Cell-specific Targeting

Overview
Journal Elife
Specialty Biology
Date 2024 Jan 9
PMID 38193894
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic toxicity is a major challenge in the development of therapeutics. Consequently, cell-type-specific targeting is needed to improve on-target efficacy while reducing off-target toxicity. Here, we describe a cell-targeting system we have termed BRAID (idged ctivation by ntra/intermolecular ivision) whereby an active molecule is divided into two inactive or less active parts that are subsequently brought together via a so-called 'bridging receptor' on the target cell. This concept was validated using the WNT/β-catenin signaling system, demonstrating that a multivalent WNT agonist molecule divided into two inactive components assembled from different epitopes via the hepatocyte receptor βKlotho induces signaling specifically on hepatocytes. These data provide proof of concept for this cell-specific targeting strategy, and in principle, this may also allow activation of multiple signaling pathways where desirable. This approach has broad application potential for other receptor systems.

Citing Articles

Design principles and therapeutic applications of novel synthetic WNT signaling agonists.

Post Y, Lu C, Fletcher R, Yeh W, Nguyen H, Lee S iScience. 2024; 27(6):109938.

PMID: 38832011 PMC: 11145361. DOI: 10.1016/j.isci.2024.109938.


A WNT mimetic with broad spectrum FZD-specificity decreases fibrosis and improves function in a pulmonary damage model.

Patel M, Post Y, Hill N, Sura A, Ye J, Fisher T Respir Res. 2024; 25(1):153.

PMID: 38566174 PMC: 10985870. DOI: 10.1186/s12931-024-02786-2.

References
1.
Janda C, Waghray D, Levin A, Thomas C, Garcia K . Structural basis of Wnt recognition by Frizzled. Science. 2012; 337(6090):59-64. PMC: 3577348. DOI: 10.1126/science.1222879. View

2.
Yie J, Wang W, Deng L, Tam L, Stevens J, Chen M . Understanding the physical interactions in the FGF21/FGFR/β-Klotho complex: structural requirements and implications in FGF21 signaling. Chem Biol Drug Des. 2012; 79(4):398-410. DOI: 10.1111/j.1747-0285.2012.01325.x. View

3.
Micanovic R, Raches D, Dunbar J, Driver D, Bina H, Dickinson C . Different roles of N- and C- termini in the functional activity of FGF21. J Cell Physiol. 2009; 219(2):227-34. DOI: 10.1002/jcp.21675. View

4.
Sato T, Stange D, Ferrante M, Vries R, van Es J, van den Brink S . Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 2011; 141(5):1762-72. DOI: 10.1053/j.gastro.2011.07.050. View

5.
Zhang J, Li Y . Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders. Front Endocrinol (Lausanne). 2015; 6:168. PMC: 4633491. DOI: 10.3389/fendo.2015.00168. View